Illumina forecasts 2025 revenue largely below estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Barclays Downgrades Illumina (ILMN) to Underweight
February 10, 2025 6:13 AM ESTBarclays analyst Luke Sergott downgraded Illumina (NASDAQ: ILMN) from Equalweight to Underweight with a price target of $100.00 (from $130.00).
The analyst comments "Overall, we view ILMN as a great business with a technological edge that has matured along with the market it created. We think that it is a normal Tools business not unlike other mature genomics / proteomics markets like PCR and mass spec. These are solid MSD topline growers with an oligopoly... More
TD Cowen Downgrades Illumina (ILMN) to Hold
February 7, 2025 7:38 AM ESTTD Cowen analyst Dan Brennan downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $140.00 (from $177.00).
The analyst comments "We downgrade to Hold post 4Q due to sev. factors: 1) accelerating high throughput (HTP) NGS consumable growth (via... More
